High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience

Böhm, Alexandra; Piribauer, Maria; Wimazal, Friedrich; Geissler, Klaus; Gisslinger, Heinz; Knöbl, Paul; Jäger, Ulrich; Fonatsch, Christa; Kyrle, Paul A.; Valent, Peter; Lechner, Klaus; Sperr, Wolfgang R.

doi:10.1016/j.leukres.2004.10.009

« Previous Next »Leukemia Research
Volume 29, Issue 6 , Pages 609-615, June 2005

High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience

Alexandra Böhm
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Maria Piribauer
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Friedrich Wimazal
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Klaus Geissler
- Fifth Medical Department – Oncology, Hospital Lainz, Vienna, Austria
Heinz Gisslinger
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Paul Knöbl
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Ulrich Jäger
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Christa Fonatsch
- Institute of Medical Biology, Vienna, Austria
Paul A. Kyrle
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Peter Valent
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Klaus Lechner
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Wolfgang R. Sperr
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
- Corresponding author. Tel.: +43 1 40400 6085; fax: +43 1 402 69 30.

Received 14 July 2004; accepted 26 October 2004.

Abstract

High dose intermittent ARA-C (2×3g/m² i.v., days 1, 3, 5)=HiDAC was introduced as consolidation in AML by the CALGB-group in 1994. We treated 44 de novo AML patients in CR with up to four cycles of HiDAC (four cycles: 56.8%; three cycles: 22.7%; two cycles: 6.8%; one cycle: 13.7%). Median duration of aplasia (ANC<0.5×10⁹/l) was 12 days. Neutropenic fever occurred in 38.6% of the patients during the first, 52.6% during the second, 45.7% during the third, and in 40% during the fourth cycle. Non-hematologic toxicity was tolerable. The median overall- and disease-free survival were 19.3 and 11.3 months, respectively. The best outcome was seen in patients aged <40 years. These results confirm that HiDAC is a safe and effective consolidation in AML.